TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis

被引：0
|
作者：
M. Cole
C. Yap
C. Buckley
W. F. Ng
I. McInnes
A. Filer
S. Siebert
A. Pratt
J. D. Isaacs
D. D. Stocken
机构：
[1] Newcastle University,Population Health Sciences Institute
[2] The Institute of Cancer Research,Clinical Trials and Statistics Unit
[3] London,School of Immunity and Infection
[4] University of Birmingham,Translational and Clinical Research Institute
[5] Newcastle University,College of Medical, Veterinary and Life Sciences
[6] University of Glasgow,Leeds Institute of Clinical Trials Research
[7] University of Leeds,undefined
来源：
Trials | / 22卷
关键词：
CRM; Dose-finding; Adaptive; Early-phase; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis
    Cole, M.
    Yap, C.
    Buckley, C.
    Ng, W. F.
    McInnes, I.
    Filer, A.
    Siebert, S.
    Pratt, A.
    Isaacs, J. D.
    Stocken, D. D.
    TRIALS, 2021, 22 (01)
  • [2] CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis
    Tesser, John
    Black, Shawn
    Lin, Rongshuang
    Langholff, Wayne
    Uy, Jonathan
    Kafka, Shelly
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
    North, Bernard
    Kocher, Hemant Mahendrakumar
    Sasieni, Peter
    BMC CANCER, 2019, 19 (1)
  • [4] A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
    Bernard North
    Hemant Mahendrakumar Kocher
    Peter Sasieni
    BMC Cancer, 19
  • [5] Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial
    Pratt, Arthur G.
    Siebert, Stefan
    Cole, Michael
    Stocken, Deborah D.
    Yap, Christina
    Kelly, Stephen
    Shaikh, Muddassir
    Cranston, Amy
    Morton, Miranda
    Walker, Jenn
    Frame, Sheelagh
    Ng, Wan-Fai
    Buckley, Christopher D.
    McInnes, Iain B.
    Filer, Andrew
    Isaacs, John D.
    LANCET RHEUMATOLOGY, 2021, 3 (05): : E337 - E346
  • [6] Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials
    Pickles, Tim
    Christensen, Robin
    Tam, Lai-Shan
    Simon, Lee S.
    Choy, Ernest H.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2018, 2 (02)
  • [7] Design of a dose escalation phase 1/2 trial for a novel combined cell and oncolytic viral therapy
    Contag, Pamela R.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] A phase 1, single dose escalation study of IL-1 Trap in patients with rheumatoid arthritis.
    Guler, HP
    Caldwell, J
    Littlejohn, T
    McIlwain, H
    Offenberg, H
    Stahl, N
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S370 - S370
  • [9] A Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis
    Anne Whitehead
    Helene Thygesen
    Vladimir Dragalin
    John Whitehead
    Trials, 12 (Suppl 1)
  • [10] OUTCOMES OF THE RAPID DOSE ESCALATION OF METHOTREXATE IN JAPANESE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS; RESULTS FROM A RANDOMIZED CONTROLLED TRIAL
    Tsutsumino, M.
    Sakai, R.
    Kihara, M.
    Amano, K.
    Yoshimi, R.
    Inoo, M.
    Dobashi, H.
    Sugihara, T.
    Hidaka, T.
    Kohsaka, H.
    Miyasaka, N.
    Harigai, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 265 - 266
12345